Mannitol
Also known as: Mannitol injection
A polyol with food-formulation uses and separate monitored intravenous pressure-lowering treatment, each with its own safety context.

Mannitol is a sugar alcohol used in specified foods and as an intravenous osmotic medicine. The injection can lower intracranial or intraocular pressure under clinical monitoring. Evidence for pressure reduction leaves long-term neurological recovery uncertain. Food intake has separate use conditions and a laxative-effect labeling threshold.1, 2, 3
- U.S. food rules require a laxative-effect warning when foreseeable consumption may result in 20 g/day of mannitol.1
- The cited injection label covers reduction of intracranial pressure, cerebral edema and elevated intraocular pressure.2
- A 47-person severe brain-injury trial measured pressure and circulation responses after equiosmolar infusions.4
What is Mannitol?
U.S. food rules describe a hexahydric alcohol manufactured by sugar reduction or specified fermentation processes. The cited medical product is a sterile 20% intravenous solution. Route, purity, concentration and clinical purpose determine the evidence that applies.1, 2
Where it comes from
Natural sources
- Sugars such as glucose or fructose are starting materials described in the food rule.
How it's made
Authorized manufacturing routes include reduction or specified fermentation of sugars and sugar alcohols. The medical preparation has separate sterile-injection specifications.
What it does in products
Benefits
Acute pressure reduction in a monitored medical setting
moderate evidenceA physiological endpoint has a defined clinical scope.4, 3, 2
The 47-person trial found that mannitol and hypertonic saline reduced intracranial pressure, while six-month neurological outcomes showed no significant difference. The 2020 guideline supports mannitol as an alternative in selected traumatic brain injury cases and rates much of the comparative evidence as low quality.
Evidence scope and limitations
Specified oral food uses and selected monitored IV pressure-lowering evidence. Specialist inhalation preparations require a separate assessment.
- The 2011 primary trial was checked through its original indexed abstract. Its sample and infusion comparator limit broader outcome conclusions.
- The accessed injection listing shows an October 2025 update while its prescribing text is revised May 2020. Those dates are distinct from today's source check.
- The 2020 guideline's TBI recommendations are conditional and supported by low-quality comparative evidence. Acute pressure response leaves long-term neurological benefit uncertain.
Evidence last checked: 2026-11-16
Side effects & safety
Safety considerations
- The injection label reports placental transfer and potential fetal fluid shifts. Clinical need and pregnancy or breastfeeding circumstances require assessment by the treating team.
- The injection label advises avoiding nephrotoxic drugs and other diuretics when possible because of renal risk. It also identifies neurotoxic and electrolyte-sensitive medicines for clinical review.
- Not for: Patients with known mannitol hypersensitivity, anuria, severe hypovolemia or pre-existing pulmonary vascular congestion/pulmonary edema, under the cited IV label.
- Not for: Patients with active intracranial bleeding, under the cited IV label, with its exception during craniotomy.
Amounts studied & product use
These figures describe research or common product use, not a personal dose or treatment recommendation.
Across food rules and an IV research protocol
The 2011 monitored trial used 20% mannitol at 4 mL/kg as its equiosmolar-comparison protocol. Medical dosing depends on the indication and monitored response. Food rules specify category limits, such as 31% in chewing gum and less than 2.5% in other covered foods. These contexts provide no universal oral supplement amount.
Regulatory status
- 21 CFR 180.25 specifies conditions for mannitol food use. The separate DailyMed injection record is a prescription-drug label under an approved new drug application. The food regulation and injection label each retain their own route and use conditions.
Pressure control and recovery are different endpoints
The 2020 guideline conditionally favors hypertonic sodium solutions for initial traumatic brain injury management, based on low-quality evidence, while retaining mannitol as an alternative when suitable. It cautions that improved neurological outcomes remain unestablished for either agent.
The older randomized trial supplies a useful physiological comparison, with only 47 patients and a particular infusion protocol. Its pressure response leaves survival or recovery benefits uncertain. Kidney function and fluid status also influence clinical selection.
3, 4, 2Frequently asked questions
The bottom line
Keep mannitol's food conditions, administration route and measured clinical endpoint attached to its claims.
References
- 21 CFR 180.25 — Mannitol. U.S. Food and Drug Administration / eCFR · government guidance · Current food regulation checked November 16, 2026 for identity, manufacture, food-category levels and foreseeable 20 g/day laxative-effect warning
- Mannitol injection, 20% — prescribing information. ICU Medical Inc. / DailyMed (2025) · ingredient monograph · SPL set ID ba7bf864-8a4d-4262-8fd1-00174fa2f9d1; accessed listing shows updated October 24, 2025 and prescribing text revised May 2020; route, indication, contraindications and monitoring checked
- Cook AM, Jones GM, Hawryluk GWJ, et al.. Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients. Neurocritical Care (2020) · clinical guideline · PMID 32227294; DOI 10.1007/s12028-020-00959-7; 32:647–666, published online May 15, 2020; full TBI recommendations and renal-monitoring discussion checked
- Cottenceau V, Masson F, Mahamid E, et al.. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma (2011) · randomized trial · PMID 21787184; DOI 10.1089/neu.2011.1929; October 2011, 28(10):2003–2012; indexed original abstract checked, full text unavailable
Revision history
- Initial AI-assisted source compilation with claim-level citations, formulation distinctions and explicit evidence limitations; not independent medical review.